Neurofibromatosis 2
Showing 1 - 25 of >10,000
Natural History Study of Patients With Neurofibromatosis Type 2
Recruiting
- Neurofibromatosis
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 25, 2023
89Zr-Bevacizumab PET/CT Imaging in NF2 Patients
Recruiting
- Neurofibromatosis 2
- Bevacizumab Zirconium Zr-89
-
Leiden, Zuid-Holland, NetherlandsLeiden University Medical Center
Jan 5, 2023
Neurofibromatosis 2, Progressive Vestibular Schwannoma (VS) Trial in United States (Crizotinib)
Active, not recruiting
- Neurofibromatosis 2
- Progressive Vestibular Schwannoma (VS)
-
Birmingham, Alabama
- +16 more
Jan 3, 2023
Neurofibromatosis Type 2, Neuroma, Acoustic Trial in Los Angeles (RAD001, everolimus)
Active, not recruiting
- Neurofibromatosis Type 2
- Neuroma, Acoustic
- RAD001, everolimus
-
Los Angeles, CaliforniaUniversity of California Los Angeles
Mar 2, 2022
Neurofibromatosis Type 2, Vestibular Schwannomas Trial in New York (Axitinib)
Completed
- Neurofibromatosis Type 2
- Vestibular Schwannomas
-
New York, New YorkNYU Langone Medical Center
Nov 24, 2021
Neurofibromatoses, Neurofibromatosis 1, Neurofibromatosis 2 Trial in Boston (Stress and Symptom Management Program 1, Stress and
Recruiting
- Neurofibromatoses
- +3 more
- Stress and Symptom Management Program 1
- Stress and Symptom Management Program 2
-
Boston, MassachusettsMassachusetts General Hospital
Sep 7, 2021
Neurofibromatosis 1, Neurofibromatosis 2, Schwannomatosis Trial in New York
Recruiting
- Neurofibromatosis 1
- +2 more
-
New York, New YorkChildren's Tumor Fundation
Jul 29, 2021
Disfigurement From Photographs of Neurofibromatosis Type 1
Completed
- Neurofibromatosis 1
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Neurofibromatosis 1 (NF1), Plexiform Neurofibromas (PN) Trial run by the NCI (Selumetinib)
Active, not recruiting
- Neurofibromatosis 1 (NF1)
- Plexiform Neurofibromas (PN)
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 31, 2023
Vestibular Schwannoma, Neurofibromatosis Type 2 Trial in Beijing (Icotinib)
Completed
- Vestibular Schwannoma
- Neurofibromatosis Type 2
-
Beijing, Beijing, China
- +1 more
Sep 8, 2021
Vestibular Schwannoma, Inner Ear Disease, Dizziness Trial in Boston (VOR precision training)
Enrolling by invitation
- Vestibular Schwannoma
- +4 more
- VOR precision training
-
Boston, MassachusettsMassachusetts Eye and Ear Infirmary
Sep 21, 2021
Familial Investigations of Childhood Cancer Predisposition
Recruiting
- Acute Leukemia
- +45 more
-
Memphis, TennesseeSt. Jude Children's Research Hospital
May 11, 2022
Hypertension, Neurofibromatosis 1, Blood Pressure Trial in Parkville (Group 1. Standard Home Blood Pressure Measurement, Group
Not yet recruiting
- Hypertension
- +2 more
- Group 1. Standard Home Blood Pressure Measurement
- Group 2. Hypnosis script prior to home blood pressure measurement
-
Parkville, Victoria, AustraliaMurdoch Children's Research Institute
Feb 8, 2022
Advanced Data Analytics in Genetic Conditions
Not yet recruiting
- Neurofibromatosis
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
Neurofibromatosis Type 2, Progressive Vestibular Schwannomas Trial in United States (Bevacizumab)
Completed
- Neurofibromatosis Type 2
- Progressive Vestibular Schwannomas
-
Los Angeles, California
- +11 more
Jan 26, 2021
Cutaneous Neurofibroma, Neurofibromatosis 1 Trial in United States (NFX-179 gel, Vehicle gel)
Recruiting
- Cutaneous Neurofibroma
- Neurofibromatosis 1
- NFX-179 gel
- Vehicle gel
-
Little Rock, Arkansas
- +22 more
Jan 18, 2023
Malignant Peripheral Nerve Sheath Tumors, Neurofibromatosis 1 Trial in United States (Selumetinib, Sirolimus)
Active, not recruiting
- Malignant Peripheral Nerve Sheath Tumors
- Neurofibromatosis 1
-
Washington, District of Columbia
- +4 more
Apr 1, 2022
Neurofibromatosis 1 and 2 (NF1 and NF2) Trial in New York (hand-held dynamometer)
Completed
- Neurofibromatosis 1 and 2 (NF1 and NF2)
- hand-held dynamometer
-
New York, New YorkNew York School of Medicine
Mar 16, 2021
Neurofibromatoses Trial in Boston (Stress and Symptom Management Program 1, Stress and Symptom Management Program 2)
Recruiting
- Neurofibromatoses
- Stress and Symptom Management Program 1
- Stress and Symptom Management Program 2
-
Boston, MassachusettsMassachusetts General Hospital
Sep 7, 2021
NF1, Congenital Pseudarthrosis of Tibia Trial in Australia, United States (INFUSE Bone Graft (BMP-2), Control Group)
Terminated
- NF1
- Congenital Pseudarthrosis of Tibia
- INFUSE Bone Graft (BMP-2)
- Control Group
-
Birmingham, Alabama
- +15 more
Sep 29, 2021
Plexiform Neurofibroma, Neurofibromatosis Type 1 (NF1) Trial in United States (Mirdametinib (PD-0325901) oral capsule or
Active, not recruiting
- Plexiform Neurofibroma
- Neurofibromatosis Type 1 (NF1)
- Mirdametinib (PD-0325901) oral capsule or dispersible tablet
-
Birmingham, Alabama
- +49 more
Nov 17, 2022
Vestibular Schwannoma, NF2, Neurofibromatosis 2 Trial in United States (lapatinib)
Completed
- Vestibular Schwannoma
- +4 more
-
Los Angeles, California
- +6 more
Dec 22, 2020
Development of Non-Invasive Prenatal Diagnosis for Single Gene
Not yet recruiting
- Invasive PreNatal Diagnosis in a Context of Family History of Single-gene Disorders, Including
- +14 more
- Blood sample
-
Paris, FranceHôpital Cochin, Maternité Port-Royal, service de Gynécologie obs
Nov 24, 2023
Neurofibroma, Plexiform Trial in Indianapolis (Imatinib Mesylate)
Withdrawn
- Neurofibroma, Plexiform
- Imatinib Mesylate
-
Indianapolis, IndianaRiley Hospital for Children - Indiana University
Feb 9, 2021